PlateletBio
Bruce Beutel, Ph.D. is a Venture Partner of the Qiming U.S. Healthcare Fund. Previously, he served as Chief Operating Officer and Chief Business & Strategy Officer at Dewpoint Therapeutics, Chief Business Officer at SQZ Biotechnologies, and Executive Director, Business Development at Merck.
He currently serves as an Independent Director on the Boards of GRO Biosciences and Boston Immune Technologies & Therapeutics.
Bruce received his B.A. in Biology from the University of Chicago and his Ph.D. in Molecular Biology from the University of Wisconsin-Madison in the lab of M. Thomas Record, Jr.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
PlateletBio
PlateletBio is the only allogeneic cell therapy company focused on platelet biology. The company's approach is one-of-a-kind, recreating nature’s legendary delivery cell. In doing so, they're developing a superior cell therapy empowered to tackle previously unmet medical challenges.